HRT Financial’s Day One Biopharmaceuticals DAWN Stock Holding History

HRT Financial’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-37,944	Closed	-$813K	–	4422
2026 Q1	$813K	Sell	37,944 -412,994	-92%	-$5.82M	﹤0.01%	2186
2025 Q4	$4.2M	Buy	450,938 +129,561	+40%	+$1.08M	0.01%	863
2025 Q3	$2.26M	Buy	+321,377	New	+$2.21M	0.01%	1078
2025 Q2	–	Sell	-31,487	Closed	-$249K	–	2782
2025 Q1	$249K	Buy	+31,487	New	+$339K	﹤0.01%	1878
2024 Q3	–	Sell	-98,624	Closed	-$1.36M	–	2552
2024 Q2	$1.36M	Buy	+98,624	New	+$1.44M	0.01%	876
2024 Q1	–	Sell	-73,887	Closed	-$1.08M	–	2461
2023 Q4	$1.08M	Buy	+73,887	New	+$896K	0.01%	944
2022 Q3	–	Sell	-35,426	Closed	-$634K	–	2937
2022 Q2	$634K	Buy	+35,426	New	+$366K	0.01%	1318

Other funds holding DAWN

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

HRT Financial's DAWN Position: Q2 2026 in Review

HRT Financial sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 37,944 shares — an estimated $813K sold.

HRT Financial first reported a position in DAWN in Q2 2022 and held it in 7 quarters. The position peaked at $4.2M in Q4 2025. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.

HRT Financial reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
HRT Financial sold 37,944 Day One Biopharmaceuticals shares in Q2 2026, an estimated $813K.
HRT Financial first reported a position in Day One Biopharmaceuticals in Q2 2022 and held it in 7 quarters.
HRT Financial's Day One Biopharmaceuticals position peaked at $4.2M in Q4 2025.
1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.